Abstract:Diffuse pleural mesothelioma (DPM) is a biologically unusual, aggressive asbestos-associated cancer affecting the entire pleura surface. DPM defies current standard multimodal therapies due to intrinsic chemoresistance and inability to achieve negative-margin resection of complex surface anatomy. Hence, current non-specific drug regimens ultimately fail because the biology of this tumor is poorly understood and even if surgically resected, tumor inevitably recurs from residual microscopic tumor foci. These various clinical challenges led us to develop a therapeutic platform delivering microRNA (miRNA), a novel anti-cancer agent therapeutic regimen, with the goal of eradicating residual microscopic tumor foci thereby improving the efficacy of multimodal therapy. We engineered a peptide-based biodegradable hydrogel that can be injected or sprayed directly to coat anatomic surfaces (surface-fill hydrogel; SFH), functioning as a therapeutic depot. Properties of SFH allow us to specify critical composition parameters such as biopersistence time, therapeutic payload, cell-specific targeting etc. In the first step of SFH formulation, miRNA complexed with different amphiphilic cationic peptides varying in length (19-26 amino acids) and amines (9-17), to form stable nanoparticles. Flash nanocomplexation (FNC) were used to produce highly scalable and kinetically controlled assembly of miRNA-peptide polyelectrolyte complex (PEC) nanoparticles (NPs), which utilizes a confined impinging jet (CIJ) mixer to achieve turbulent micromixing of the NPs components, yielding highly uniform and stable NPs. Next, NPs were encapsulated into another peptide hydrogel, formed via self-assembly of amphiphilic cationic peptide HLT2, thus forming a surface-fill hydrogel NPs composite. The SFH-NPs composite was not toxic to DPM cells and demonstrated efficient release of miRNA-peptide NPs from the SFH matrix in-vitro. The uptake of FAM-labeled miRNA-peptide NPs was confirmed by flowcytometry. Biodistribution analysis of NPs in mice bearing luciferase-positive DPM xenografts treated locally with Cy3-miRNA-SFH composite showed that Cy3-miRNA was concentrated in tumor cells but not in other organs. Furthermore, miR-215 exhibiting potent anti-tumor activity in DPM was used to study the therapeutic efficacy of SFH miRNA-nanoparticle composites. Subcutaneous DPM xenografts treated locally with miR-215 SFH composite shrank tumor significantly. Thus, delivery of specific miRNA-peptide PEC nanoparticles via SFH therapeutic platform in preclinical models of DPM displayed potent anti-cancer effects. Together, this new generation microRNA-peptide polyelectrolyte complex nanoparticles-SFH composite is a very promising delivery platform that could be extended for a diverse array of locoregional therapies. Citation Format: Anand Singh, Anderson Caleb, Joel P. Schneider, Chuong D. Hoang. MicroRNA-peptide polyelectrolyte complex nanoparticle-hydrogel composite attenuates mesothelioma growth [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3205.

Kinetically Controlled Polyelectrolyte Complex Assembly of microRNA‐Peptide Nanoparticles toward Treating Mesothelioma

Abstract 3205: MicroRNA-peptide polyelectrolyte complex nanoparticle-hydrogel composite attenuates mesothelioma growth

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

Linear-like polypeptide-based micelle with pH-sensitive detachable PEG to deliver dimeric camptothecin for cancer therapy

Self-modifying NanoEnhancers Facilitating Lysosomal Escape for Cgas-Sting Cascading Activation in Tumor Immunotherapy

A Mesoporous Silica Nanoparticle--pei--fusogenic Peptide System for Sirna Delivery in Cancer Therapy.

Tumor‐Specific Protein Induced in Situ Self‐Assembly of Peptide Drugs for Synergistic Mitochondria Disruption

Peptide-functionalised magnetic silk nanoparticles produced by a swirl mixer for enhanced anticancer activity of ASC-J9

A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis‐targeting Chimeras Enhanced Immunotherapy

Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer

Peptide-Induced Self-Assembly of Therapeutics into a Well-Defined Nanoshell with Tumor-Triggered Shape and Charge Switch

Co-delivery of siRNA and cisplatin via electrospun Nanofibrous membranes for synergistic treatment of malignant melanoma

Systemic siRNA delivery to tumors by cell-penetrating α-helical polypeptide-based metastable nanoparticles

Enzyme-Mimetic, Cascade Catalysis-Based Triblock Polypeptide-Assembled Micelles for Enhanced Chemodynamic Therapy.

Fabrication of a multifunctional nanomaterial from a mussel-derived peptide for multimodal synergistic cancer therapy

Development of a Rapid-Onset, Acid-Labile Linkage Polyplex-Mixed Micellar System for Anticancer Therapy

Chemo-immunotherapy by dual-enzyme responsive peptide self-assembling abolish melanoma

An Injectable Composite Co‐Assembled Dehydropeptide‐Based Magnetic/Plasmonic Lipogel for Multimodal Cancer Therapy

Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.

Enhanced chemotherapy and anti-metastasis with in situ nanosphere-to-nanofiber transition

Engineered (NH2)-MIL-125(Ti)/copolymer@MnFe2O4 nanocomposite for synergistic eradication of cancer cells via DOX/pCRISPR delivery